Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.78 |
| ▸ | CASP7 | P55210 | 1/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.78 |
| ▸ | MAOB | P27338 | 12/20 | 0.56 |
| ▸ | MAOA | P21397 | 11/20 | 0.56 |
| ▸ | PRKCI | P41743 | 1/20 | 0.56 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5113010 | 0.98 | CASP1 (0.75) | CASP1CASP7HSD17B10MAOBMAOA | |
| SCHEMBL929312 | 0.96 | CASP1 (0.78) | CASP1CASP7HSD17B10MAOBMAOA | |
| Hydrochloric Acid SCHEMBL23671046 | 0.94 | CASP1 (0.75) | CASP1CASP7HSD17B10MAOBMAOA | |
| Sulfuric Acid SCHEMBL315860 | 0.88 | CASP1 (0.66) | CASP1CASP7HSD17B10MAOBMAOA | |
| SCHEMBL434358 | 0.88 | CASP1 (1.00) | CASP1CASP7HSD17B10MAOBMAOA | |
| Hydrochloric Acid SCHEMBL27821207 | 0.86 | CASP1 (0.96) | CASP1CASP7HSD17B10MAOBMAOA | |
| SCHEMBL4878376 | 0.84 | CASP1 (0.55) | CASP1CASP7HSD17B10MAOBMAOA | |
| Nitrogen SCHEMBL28460322 | 0.84 | CASP1 (0.92) | CASP1CASP7HSD17B10MAOBMAOA | |
| SCHEMBL656011 | 0.80 | CASP1 (0.55) | CASP1CASP7HSD17B10MAOBMAOA | |
| SCHEMBL30067461 | 0.80 | CASP1 (0.55) | CASP1CASP7HSD17B10MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016025933-A2 | SUBSTITUTED POLYCYCLIC ANTIBACTERIAL COMPOUNDS | PTC THERAPEUTICS, INC. (US) | 2016-02-18 | — | — | WO | disclosed |
| US-8809396-B2 | Substituted fused-ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809396-B2 | Substituted fused-ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809396-B2 | Substituted fused-ring compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-19 | — | — | US | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2011-03-03 | — | — | US | disclosed |
| EP-2240029-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corp. (US) | 2010-10-20 | — | — | EP | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2009089305-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2009-07-16 | — | — | WO | disclosed |
| WO-2008103310-A1 | SUBSTITUTED FUSED-RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008103310-A1 | SUBSTITUTED FUSED-RING COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2008-08-28 | — | — | WO | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| US-20070249583-A1 | HMG-CoA reductase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-25 | — | — | US | disclosed |
| EP-1230244-B1 | PYRAZOLECARBOXYLIC ACID TRICYCLIC DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI AVENTIS (FR) | 2005-01-19 | — | — | EP | disclosed |
| EP-1230244-A2 | PYRAZOLECARBOXYLIC ACID TRICYCLIC DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Sanofi-Aventis (FR) | 2002-08-14 | — | — | EP | disclosed |
| WO-2001032663-A2 | PYRAZOLECARBOXYLIC ACID TRICYCLIC DERIVATIVES, PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | SANOFI-SYNTHELABO (FR) | 2001-05-10 | — | — | WO | disclosed |
| JP-2000007606-A | PRODUCTION OF 7-(2-FLUOROPHENYL)-1-BENZOSUBERONE | KYOWA HAKKO KOGYO CO LTD | 2000-01-11 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249583-A1 | HMG-CoA reductase inhibitors | HMGCR, LDLR, PCSK9 | CASP1 3732/4885CASP7 3328/4885HSD17B10 30/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | CASP1 2471/4885CASP7 1873/4885HSD17B10 4144/4885 |
| US-20110052643-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | TSLP, NFATC1, IL5 | CASP1 216/4885CASP7 640/4885HSD17B10 2246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.